The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure

About 5 million Americans suffer from heart failure. Given the correlation of heart failure with age and the rising life expectancy, the prevalence of heart failure continues to increase in the general population. Sympathetic stimulation intensifies with progressive heart failure. The rationale to u...

Full description

Bibliographic Details
Main Authors:	De Freitas, Ovidio, Lenz, Oliver, Fornoni, Alessia, Materson, Barry J
Format:	Online
Language:	English
Published:	Dove Medical Press 2006
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994002/

id	pubmed-1994002
recordtype	oai_dc
spelling	pubmed-19940022008-03-06 The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure De Freitas, Ovidio Lenz, Oliver Fornoni, Alessia Materson, Barry J Review About 5 million Americans suffer from heart failure. Given the correlation of heart failure with age and the rising life expectancy, the prevalence of heart failure continues to increase in the general population. Sympathetic stimulation intensifies with progressive heart failure. The rationale to use β-blockers in individuals with impaired myocardial function is based on experimental evidence supporting the notion that prolonged α- and β-adrenergic stimulation leads to worsening heart failure. Until recently, safety concerns have precluded the use of β-blockers in patients with diabetes and heart failure. However, several large, randomized, placebo-controlled clinical trials such as Metoprolol Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) have shown that β-blockers can be safely used in patients with diabetes and heart failure. Moreover, β-blockers significantly improved morbidity and mortality in this population. Based on this evidence, it is now recommended to add β-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis. Dove Medical Press 2006-06 2006-06 /pmc/articles/PMC1994002/ /pubmed/17319457 Text en © 2006 Dove Medical Press Limited. All rights reserved
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	De Freitas, Ovidio Lenz, Oliver Fornoni, Alessia Materson, Barry J
spellingShingle	De Freitas, Ovidio Lenz, Oliver Fornoni, Alessia Materson, Barry J The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure
author_facet	De Freitas, Ovidio Lenz, Oliver Fornoni, Alessia Materson, Barry J
author_sort	De Freitas, Ovidio
title	The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure
title_short	The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure
title_full	The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure
title_fullStr	The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure
title_full_unstemmed	The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure
title_sort	use of metoprolol cr/xl in the treatment of patients with diabetes and chronic heart failure
description	About 5 million Americans suffer from heart failure. Given the correlation of heart failure with age and the rising life expectancy, the prevalence of heart failure continues to increase in the general population. Sympathetic stimulation intensifies with progressive heart failure. The rationale to use β-blockers in individuals with impaired myocardial function is based on experimental evidence supporting the notion that prolonged α- and β-adrenergic stimulation leads to worsening heart failure. Until recently, safety concerns have precluded the use of β-blockers in patients with diabetes and heart failure. However, several large, randomized, placebo-controlled clinical trials such as Metoprolol Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) have shown that β-blockers can be safely used in patients with diabetes and heart failure. Moreover, β-blockers significantly improved morbidity and mortality in this population. Based on this evidence, it is now recommended to add β-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis.
publisher	Dove Medical Press
publishDate	2006
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994002/
_version_	1611401451617124352

The Use of Metoprolol CR/XL in the Treatment of Patients with Diabetes and Chronic Heart Failure

Similar Items